PFE · 8-K · 20260804PR000094

Legal Matters and ViiV Sale

PFIZER INC · 2026-08-04 · Importance 55 · Surprise 60 · No source text

Pfizer recorded a $1.870 billion net gain in the second quarter and first six months from selling its previous investment in ViiV. The gain was partially offset by $867 million of second-quarter charges and $1.0 billion of six-month charges for certain legal matters, primarily product liability and other legal expenses. The resulting second-quarter adjustment to Other income/deductions—net was a $1.0 billion gain, while the six-month adjustment was an $850 million gain. The company reported $25 million of certain legal matters, net, in non-GAAP adjusted Other income/deductions—net for the second quarter and $19 million for the six-month period.

Key facts

• For the second quarter and first six months of 2026, Other (income)/deductions––net adjustments of $1.0 billion and $850 million, respectively, primarily include a net gain of $1.870 billion and charges of $867 million and $1.0 billion for legal matters source
• Net gain from the sale of investment in ViiV Healthcare Limited: $1,870 million (included in Other income/deductions—net) source
• For the second quarter and first six months of 2025, Other (income)/deductions––net adjustments were $512 million and $678 million, primarily included charges of $422 million and $564 million for certain legal matters source

Impact estimates